The Expanding Treatment Armamentarium and Clinical Decision Making: ExteNET, DestinyBREAST-05, HER2CLIMB, and Other Emerging Trials
Dr. Tarantino discuss the integration of recent trial data into post-neoadjuvant treatment strategies, comparing adjuvant T-DM1 with pertuzumab plus trastuzumab.
Video content above is prompted by the following:
- How might these data factor into your treatment considerations post neoadjuvant treatment?
- When would you recommend adjuvant T-DM1 over adjuvant pertuzumab plus trastuzumab in this setting?
- With a growing number HER2-targeting agents available, how do you approach the decision-making process in your practice? Please comment on other trials investigating HER2 targeting agents?
- Trastuzumab
- Tucatinib
- Neratinib
- How do you evaluate and compare data from clinical trials for these agents?
- What are the factors you consider when selecting between HER2-targeted agents?
- What are your considerations for optimal sequencing of these therapies?
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
